Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Lianhuan Pharmaceutical’s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial

Fineline Cube Apr 30, 2026
Company Drug

Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations

Fineline Cube Apr 30, 2026
Company Deals

Adicon Holdings Ltd IPO: A Strategic Move for Growth in Diagnostics

Fineline Cube Jun 19, 2023

Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory (ICL) service provider, has successfully...

Company Deals

Acotec Scientific Holdings and Boston Scientific Group plc Sign MOU to Broaden Collaboration

Fineline Cube Jun 19, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced a memorandum of understanding (MoU) with...

Company Drug

Aosaikang Pharmaceutical’s ASKB589 Shows Promising Results in Solid Tumor Treatment Study

Fineline Cube Jun 19, 2023

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed the latest results from a Phase...

Company Deals

Jiangsu Hengrui Medicine Cancels Licensing Agreement with Mabworks Citing Market Changes

Fineline Cube Jun 19, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced its decision to cancel a...

Company Drug

Roche’s Evrysdi Receives NMPA Approval for Wider SMA Patient Age Range

Fineline Cube Jun 19, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that its blockbuster nervous system drug Evrysdi...

Company Drug

MicuRx Pharmaceuticals’ MRX-4/Contezolid Combo Receives Clinical Trial Approvals for Diabetic Foot Infection

Fineline Cube Jun 19, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced receiving clinical trial approvals for its...

Company Deals

AstraZeneca Enters Three-Year Collaboration with Cholesgen for Metabolic Disease Therapies

Fineline Cube Jun 19, 2023

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has signed a three-year collaboration agreement with China-based...

Company Drug

BeiGene to Showcase Brukinsa Data at ICML, Highlighting Efficacy in Relapsed Follicular Lymphoma

Fineline Cube Jun 16, 2023

China-based biopharmaceutical company BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it will...

Company Drug

Fosun Pharma Initiates Phase II Study of HLX26 and Serplulimab Combo for Metastatic CRC

Fineline Cube Jun 16, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...

Company Drug

CStone’s Sugemalimab Shows Promising Survival Rates in Stage IV NSCLC Treatment

Fineline Cube Jun 16, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced that the prestigious journal Nature Cancer has published...

Company Drug

Takeda and HutchMed’s Elunate Study Results Published in The Lancet

Fineline Cube Jun 16, 2023

Takeda (TYO: 4502) and HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) have announced that the...

Company Deals

Gates Foundation Renews Partnership with Beijing and Tsinghua to Boost Infectious Disease Research

Fineline Cube Jun 16, 2023

The Bill & Melinda Gates Foundation has announced the renewal of its collaboration with the...

Company Deals

Grifols AS Plans to Sell Stake in Shanghai RAAS Blood Products Co., Ltd for Up to $1.5 Billion

Fineline Cube Jun 16, 2023

Spain-based Grifols AS (NASDAQ: GRFS), a leading global player in the blood products industry, has...

Company Deals Digital

Sperogenix Therapeutics and LUCA Healthcare Join Forces to Advance Digital Therapy for Myasthenia Gravis

Fineline Cube Jun 16, 2023

China-based rare disease specialist Sperogenix Therapeutics Limited has entered into a partnership with compatriot firm...

Company Drug

Jiangxi Jemincare’s JYB1907 Receives NMPA Approval for Clinical Study in Solid Tumors

Fineline Cube Jun 16, 2023

China-based Jiangxi Jemincare Group has announced that it has received approval from the China National...

Company Medical Device

NMPA Approves Suzhou MicroPort Joint Medical Technology’s Zirconium Niobium Alloy Femoral Head for Hip Replacement

Fineline Cube Jun 16, 2023

The National Medical Products Administration (NMPA) has granted marketing approval to Suzhou MicroPort Joint Medical...

Company Drug

Cytocraft Biotech’s SDT-T002 Cell Therapy Approved for Advanced Liver Cancer by NMPA

Fineline Cube Jun 16, 2023

China-based Cytocraft Biotech Development has announced that its cell therapy, SDT-T002, has obtained clinical trial...

Company Deals

Laekna Raises £791 Million in Hong Kong IPO for Pipeline Expansion

Fineline Cube Jun 16, 2023

Sino-US Laekna (HKG: 2105) has successfully raised £791 million through an initial public offering (IPO)...

Company Drug

Grand Pharmaceutical’s STC3141 Achieves Clinical Endpoint in Sepsis Study

Fineline Cube Jun 16, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that the Phase Ib REFINE study...

Company

Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer to Drive Innovation

Fineline Cube Jun 16, 2023

China-based Everest Medicines (HKG: 1952) has announced the appointment of Dr. Mike Berry as Chief...

Posts pagination

1 … 507 508 509 … 659

Recent updates

  • Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline
  • Lianhuan Pharmaceutical’s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial
  • Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations
  • Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate
  • Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Company Drug

Lianhuan Pharmaceutical’s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial

Company Drug

Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations

Company Drug

Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.